Shares of Balfour Beatty plc (LON:BBY – Get Free Report) hit a new 52-week high on Thursday . The company traded as high as GBX 462.60 ($5.86) and last traded at GBX 454.20 ($5.76), with a volume of 2704056 shares changing hands. The stock had previously closed at GBX 451.40 ($5.72).
Analyst Ratings Changes
Several research analysts have commented on BBY shares. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 475 ($6.02) price target on shares of Balfour Beatty in a research report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft lifted their price target on Balfour Beatty from GBX 500 ($6.34) to GBX 575 ($7.29) and gave the stock a “buy” rating in a research report on Friday, November 22nd.
Get Our Latest Stock Report on Balfour Beatty
Balfour Beatty Trading Down 0.0 %
Insiders Place Their Bets
In other news, insider Philip Harrison sold 240,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of GBX 432 ($5.48), for a total transaction of £1,036,800 ($1,314,401.62). Also, insider Robert MacLeod acquired 17,674 shares of the stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average price of GBX 422 ($5.35) per share, for a total transaction of £74,584.28 ($94,554.11). Company insiders own 1.15% of the company’s stock.
About Balfour Beatty
Balfour Beatty plc finances, designs, develops, builds, and maintains infrastructure in the United Kingdom, the United States, and internationally. It operates through three segments: Construction Services, Support Services, and Infrastructure Investments. The company constructs buildings, including commercial, healthcare, education, retail, and residential assets; and infrastructure assets comprising highways and railways, as well as other large-scale infrastructure assets, such as waste, water, and energy plants.
Featured Stories
- Five stocks we like better than Balfour Beatty
- How to Invest in Biotech Stocks
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Quiet Period Expirations Explained
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Balfour Beatty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balfour Beatty and related companies with MarketBeat.com's FREE daily email newsletter.